Fig. 1 · Structure
Documents & Downloads
Praluzatamab ravtansine
Anti-CD166 ADC
Praluzatamab ravtansine is an anti-CD166 antibody-drug conjugate (ADC) that targets CD166 with a Kd value of 25.15 nM. This compound comprises the anti-CD166 monoclonal antibody Praluzatamab conjugated to the microtubule inhibitor DM4, facilitating targeted cytotoxicity in tumor cells. Praluzatamab ravtansine is commonly utilized in research focused on various malignancies, including lung and breast cancer, to explore its potential therapeutic applications in these areas.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2145115-85-9 |
| Applications | Anti-CD166 ADC |
| Synonyms | CX-2009; CD166 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.